Histone deacetylase inhibitors: Anticancer compounds

被引：70
作者：
Smith, Karen T. [1 ]
Workman, Jerry L. [1 ]
机构：
[1] Stowers Inst Med Res, Kansas City, MO 64110 USA
来源：
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY | 2009年 / 41卷 / 01期
关键词：
HDAC; Acetylation; Chromatin; Cancer; Cell cycle; SUBEROYLANILIDE HYDROXAMIC ACID; ESTROGEN-RECEPTOR-ALPHA; CARCINOMA-CELL-LINES; BREAST-CANCER CELLS; PML-RAR-ALPHA; VALPROIC ACID; PROTEASOMAL DEGRADATION; DNA METHYLTRANSFERASE-1; SODIUM-BUTYRATE; HDAC INHIBITORS;
D O I：
10.1016/j.biocel.2008.09.008
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
The reversible acetylation of proteins is mediated by histone acetytransferases which acetylate proteins and historic deacetylases that remove the acetyl groups. High levels of histone acetylation are correlated with active genes, while hypoacetylation of histones corresponds with gone repression. Importantly, acetylation also occurs on non-histone proteins all this call affect the activity and stability of these proteins. Aberrant epigenetic changes ate a common hallmark Of tumors and Imbalances in the activities of deacetylases have been associated with cancers. Accordingly, inhibitors to the historic deacetylases are in clinical trials for the treatment of several cancer types. These drugs mediate a number Of molecular changes and ill turn Call induce cell cycle arrest, apoptosis or differentiation of cancer cells while displaying limited toxicity in normal cells. (C) 2003 Elsevier Ltd. All rights reserved.
引用
收藏
页码：21 / 25
页数：5
相关论文
共 49 条
[1]   Histone deacetylase inhibitor trichostatin a represses estrogen receptor α-dependent transcription and promotes proteasomal degradation of cyclin D1 in human breast carcinoma cell lines [J].
Alao, JP ;
Lam, EWF ;
Ali, S ;
Buluwela, L ;
Bordogna, W ;
Lockey, P ;
Varshochi, R ;
Stavropoulou, AV ;
Coombes, RC ;
Vigushin, DM .
CLINICAL CANCER RESEARCH, 2004, 10 (23) :8094-8104
[2]   Valproic acid sensitizes chronic lymphocytic leukemia cells to apoptosis and restores the balance between pro- and antiapoptotic proteins [J].
Bokelmann, Imke ;
Mahlknecht, Ulrich .
MOLECULAR MEDICINE, 2008, 14 (1-2) :20-27
[3]   Histone deacetylase inhibitors selectively suppress expression of HDAC7 [J].
Dokmanovic, Milos ;
Perez, Gisela ;
Xu, Weisheng ;
Ngo, Lang ;
Clarke, Cathy ;
Parmigiani, Raphael B. ;
Marks, Paul A. .
MOLECULAR CANCER THERAPEUTICS, 2007, 6 (09) :2525-2534
[4]  
Fenrick R, 1998, J CELL BIOCHEM, P194
[5]   Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors [J].
Finnin M.S. ;
Donigian J.R. ;
Cohen A. ;
Richon V.M. ;
Rifkind R.A. ;
Marks P.A. ;
Breslow R. ;
Pavletich N.P. .
Nature, 1999, 401 (6749) :188-193
[6]   Role of Class I and Class II histone deacetylases in carcinoma cells using siRNA [J].
Glaser, KB ;
Li, JL ;
Staver, MJ ;
Wei, RQ ;
Albert, DH ;
Davidsen, SK .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2003, 310 (02) :529-536
[7]  
Glaser KB, 2003, MOL CANCER THER, V2, P151
[8]   Acetylation and deacetylation of non-histone proteins [J].
Glozak, MA ;
Sengupta, N ;
Zhang, XH ;
Seto, E .
GENE, 2005, 363 :15-23
[9]   Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells [J].
Göttlicher, M ;
Minucci, S ;
Zhu, P ;
Krämer, OH ;
Schimpf, A ;
Giavara, S ;
Sleeman, JP ;
Lo Coco, F ;
Nervi, C ;
Pelicci, PG ;
Heinzel, T .
EMBO JOURNAL, 2001, 20 (24) :6969-6978
[10]   Expression-based screening identifies the combination of histone deacetylase inhibitors and retinoids for neuroblastoma differentiation [J].
Hahn, Cynthia K. ;
Ross, Kenneth N. ;
Warrington, Ian M. ;
Mazitschek, Ralph ;
Kanegai, Cindy M. ;
Wright, Renee D. ;
Kung, Andrew L. ;
Golub, Todd R. ;
Stegmaier, Kimberly .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2008, 105 (28) :9751-9756
12345